Eye Health Advancements and Ongoing Challenges in Africa

By Crystal Lubbe

October 15, 2024

The article titled “Promising progress on eye health in the African region, but challenges remain” from the World Health Organization (WHO) Regional Office for Africa highlights several key points regarding the current state of eye health in the African region. While there has been notable progress in eye health, significant challenges remain that hinder further advancements.

Progress Made

Despite significant challenges, progress has been made in integrating eye health into primary health care services in African countries. The WHO has recorded a decrease in vision loss due to Vitamin A deficiency, onchocerciasis, and trachoma. These gains are critical for improving overall well-being and reducing the economic burden associated with preventable vision loss.

Challenges

A dire shortage of financial resources and the concentration of scarce human resources in urban areas continue to hinder eye health progress. This results in low community awareness and inadequate access to eye care services. Only 14% of people who need cataract surgery receive it, while more than 80% of those with shortsightedness do not receive treatment. This is in stark contrast to other regions like North America, Australasia, Western Europe, and the Asia-Pacific, where the figures are lower than 10%. The global estimated costs of uncorrected refractive errors and cataracts are significant, amounting to US$14.3 billion annually.

Emerging Challenges

There is a rising trend of eye health challenges related to aging populations, unhealthy lifestyles, and noncommunicable diseases such as diabetic retinopathy and age-related macular degeneration.

WHO’s Current Focus and Initiatives

The WHO is actively supporting countries to integrate eye health services at the primary care level as part of universal health coverage. This includes providing technical support to countries like Ethiopia, Ghana, Niger, Nigeria, Somalia, and Zambia through national situational analyses, strategic plans, and monitoring frameworks. The SPECS 2030 initiative aims to increase the number of people with access to appropriate spectacles, targeting an effective coverage of refractive error (eREC) of 40% by 2030. Liberia and Mozambique have begun implementing this initiative. Furthermore, the WHO has launched a free self-assessment tool called WHOeyes to promote healthy habits and raise eye care awareness. This tool is available in multiple languages and helps check visual acuity while providing educational messaging.

Economic and Social Impact

Good vision significantly impacts overall well-being, academic achievements, and economic growth. Therefore, addressing eye health challenges is crucial for broader societal benefits.

In summary, while there has been progress in reducing certain causes of blindness in Africa, significant challenges persist, including financial and human resource constraints, low community awareness, and emerging eye health issues related to noncommunicable diseases. The WHO is committed to addressing these challenges through various initiatives and support programs aimed at improving eye health in the African region.

Reference url

Recent Posts

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.